Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy.
Elisa MeucciAnna RadiceFilippo FassioMaria Loredana Chiara IornoDonatella MacchiaPublished in: Clinical case reports (2021)
Anaphylaxis after mosquito bite is rare, but life threatening. No approved preventive therapy is available to date, but omalizumab could be a promising therapeutic option for reducing risk and improving quality of life in these patients.